Jason Kralic | Tellus Therapeutics – Translational Biotech Platforms and Advancing Therapies for Neonatal Brain Injury

In this episode of Executive Insights for Life Sciences Innovators, we speak with Jason Kralic, CEO and co-founder of Tellus Therapeutics, a biotechnology company focused on developing novel therapies for neonatal brain injury.Jason discusses how Tellus is building a translational biotech platform grounded in strong biological insight and disciplined execution, with a clear focus on addressing one of the most complex and underserved patient populations in medicine. He shares insights from his career journey as a neuropharmacologist and life sciences business development leader, including how his experience in large pharma and biotech informs the way he evaluates scientific risk, platform focus, and company strategy.We explore the challenges of translating science into the clinic, the realities of capital strategy and timing in today’s funding environment, and Jason’s perspective on what it takes to build biotech companies designed to endure.This episode was streamed live on YouTube on January 9, 2026. Learn more at ⁠⁠genecoda.com⁠⁠.